Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor

Apoptosis

Volumn 9, Issue 2, 2004, Pages 193-204

  Stoklosa T ^a,b,d   Golab J ^a   Wojcik C ^a,e   Wlodarski P ^a   Jalili, A ^a   Januszko, P ^a   Giermasz, A ^f   Wilczynski G M ^a   Pleban, E ^a   Marczak, M ^b   Wilk, S ^c   Jakobisiak M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Temple University   (United States)

^e UNIVERSITY OF TEXAS AT DALLAS   (United States)

^f NONE

Author keywords

Angiogenesis; Apoptosis; Cancer therapy; Proteasome; VEGF

Indexed keywords

N BENZYLOXYCARBONYLISOLEUCYLGLUTAMYL(O TERT BUTYL)ALANYLLEUCINAL; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; UPREGULATION;

ANIMALIA; MURINAE;

EID: 3342880127     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000018801.59062.1d     Document Type: Article

References (41)

1. Ciechanover A, Schwartz AL. The ubiquitin-proteasome pathway: The complexity and myriad functions of proteins death. Proc Natl Acad Sci USA 1998; 95: 2727-2730.
2. Wilk S, Orlowski M. Cation-sensitive neutral endopeptidase: Isolation and specificity of the bovine pituitary enzyme. J Neurochem 1980; 35: 1172-1182.
3. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479.
4. Elledge SJ, Harper JW. The role of protein stability in the cell cycle and cancer. Biochim Biophys Acta 1998; 1377: M61-M70.
5. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today 2003; 8: 307-315.
6. Wójcik C. Inhibition of the proteasome as a therapeutic approach. Drug Discov Today 1999; 4: 188-192.
7. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
8. Aghajaman C, Soignet S, Dizon DS, et al. A phase i trial of the novel proteasome inhibitor ps341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-2511.
9. Adams J. Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 2002; 14: 628-634.
10. Wilk S, Figueiredo-Pereira M. Synthetic inhibitors of the multicatalytic proteinase complex (proteasome). Enzyme Protein 1993; 47: 306-313.
11. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997; 94: 855-860.
12. Wójcik C, Stokłosa T, Giermasz A, et al. Apoptosis induced in 11210 leukemia cells by an inhibitor of the chymotrypsin-like activity of the proteasome. Apoptosis 1997; 2: 455-462.
13. Stokłosa T, Wójcik C, Golła̧b J, Giermasz A, Wilk S. Inhibition of proteasome, apoptosis and sensitization to tumor necrosis factor alpha: Do they always go together? Br J Cancer 1999; 79: 375-376.
14. Williams RL, Courtneidge SA, Wagner EF. Embryonic lethalities and endothelial tumors in chimeric mice expressing polyoma virus middle t oncogene. Cell 1988; 52: 121-131.
15. Goła̧b J, Stokłosa T, Czajka A, et al. Synergistic antitumor effects of a selective proteasome inhibitor and tnf in mice. Anticancer Res 2000; 20: 1717-1721.
16. Majewski S, Szmurto A, Marczak M, Jabłońska S, Bollag W Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect on hpv-harboring tumor-cell lines. Int J Cancer 1994; 57: 81-85.
17. Breier G, Albrecht U, Sterrer S, Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 1992; 114: 521-532.
18. Rizzo MG, Soddu S, Tibursi G, Calabretta B, Sacchi A. Wild-type p53 differentially affects tumorigenic and metastatic potential of murine metastatic cell variants. Clin Exp Metastas 1993; 11: 368-376.
19. Lopes UG, Erhardt P, Yao R, Cooper GM. P53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem 1997; 272: 12893-12896.
20. Herrmann JL, Briones F, Jr, Brisbay S, Logothetis CJ, McDonnell TJ. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional bcl-2 and p53. Oncogene 1998; 17: 2889-2899.
21. Nicholson DW, Ali A, Thornberry NA, et al. Identification and inhibition of the ice/ced-3 protease necessary for mammalian apoptosis. Nature 1995; 376: 37-43.
22. Pagano M, Tam SW, Theodoras AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-685.
23. Orlowski RZ, Eswara JE, Lafond-Walker A, et al. Tumor growth inhibition induced in a murine model of human burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998; 58: 4342-4348.
24. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-716.
25. Subbaramaiah K, Altorki N, Chung WJ, et al. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem 1999; 274: 10911-10915.
26. Oikawa T, Sasaki T, Nakamura M, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243-248.
27. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
28. Grunstein J, Roberts WG, Mathieu-Costello O, Hanahan D, Johnson RS. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res 1999; 59: 1592-1598.
29. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes play an essential role in thymocyte apoptosis. EMBO Journal 1996; 15: 3835-3844.
30. Sadoul R, Fernandez PA, Quiquerez AL, et al. Involvement of the proteasome in the programmed cell death of ngf-deprived sympathetic neurons. EMBO Journal 1996; 15: 3845-3852.
31. Teicher B, Ara G, Herbst R, Palombella V, Adams J. The proteasome inhibitor ps-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-2645.
32. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-234.
33. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-1399.
34. Bicknell R, Harris AL. Mechanisms and therapeutic implications of angiogenesis. Curr Opinion Oncol 1996; 8: 60-65.
35. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998; 58: 2288-2292.
36. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase c induction of vascular endothelial growth factor expression. Oncogene 1994; 9: 963-969.
37. Nawrocki ST, Bruns CJ, Harbison MT, et al. Effects of the proteasome inhibitor ps-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002; 1: 1243-1253.
38. Chandra J, Niemer I, Gilbreath J, et al. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 1998; 92: 4220-4229.
39. Drexler HCA, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J 2000; 14: 65-77.
40. Blagosklonny MV, An WG, Romanova LY, et al. P53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 1998; 273: 11995-11998.
41. Kallio PJ, Wilson WJ, S OB, Makino Y, Poellinger L. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J Biol Chem 1999; 274: 6519-6525.